Amedeo Smart

Free Medical Literature Service

 

Amedeo

Dermatology
  Free Subscription

Articles published in
Lancet
    October 2025
  1. CACOUB P, Vieira M, Langford CA, Tazi Mezalek Z, et al
    Large-vessel vasculitis.
    Lancet. 2025;406:2017-2032.
    >> Share

    September 2025
  2. GOLD LS, Armstrong AW, Bissonnette R, Magnolo N, et al
    Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
    Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576.
    >> Share

  3. PUIG L
    Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy.
    Lancet. 2025 Sep 18:S0140-6736(25)01675-7. doi: 10.1016/S0140-6736(25)01675.
    >> Share

    August 2025

  4. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    >> Share

  5. BRAIN E, Mir O, Bourbouloux E, Rigal O, et al
    Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
    Lancet. 2025;406:489-500.
    >> Share

    July 2025
  6. TANG JY, Marinkovich MP, Wiss K, McCarthy D, et al
    Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.
    Lancet. 2025;406:163-173.
    >> Share

    June 2025
  7. EBENS CL
    Targeting challenging RDEB skin wounds with gene therapy.
    Lancet. 2025 Jun 23:S0140-6736(25)01154-7. doi: 10.1016/S0140-6736(25)01154.
    >> Share

    May 2025
  8. GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al
    Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
    Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582.
    >> Share

  9. GIMENEZ-ARNAU AM, Pinter A, Sondermann W, Reguiai Z, et al
    Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
    Lancet. 2025;405:1676-1688.
    >> Share

    February 2025
  10. GUTTMAN-YASSKY E, Renert-Yuval Y, Brunner PM
    Atopic dermatitis.
    Lancet. 2025;405:583-596.
    >> Share

  11. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    >> Share

  12. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    >> Share

    January 2025
  13. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    >> Share

    December 2024
  14. WEIDINGER S, Novak N
    Hand eczema.
    Lancet. 2024;404:2476-2486.
    >> Share

    November 2024
  15. CHONG DHY, Pasternak S, Taylor T, Armstrong S, et al
    Skin biopsy findings of dyskeratotic keratinocytes and vacuolar interface change in a patient with Still's disease.
    Lancet. 2024;404:e6.
    >> Share

  16. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    >> Share

    October 2024
  17. JAIRATH V, Acosta Felquer ML, Jaihyun Cho R
    IL-23 inhibition for chronic inflammatory disease.
    Lancet. 2024;404:1679-1692.
    >> Share


  18. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
    Lancet. 2024;404:1407-1418.
    >> Share

  19. TARANTINO P, Tolaney SM
    Progress in breast cancer management.
    Lancet. 2024;404:1376-1378.
    >> Share

    September 2024
  20. NARAGHI K, Marzo-Ortega H
    Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea.
    Lancet. 2024;404:e4.
    >> Share

    August 2024
  21. LEBWOHL MG, Thoma C, Haeufel T
    Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lancet. 2024;404:847-848.
    >> Share

  22. OSBORNE S, Thacker S, Kam O, Wescott R, et al
    Spesolimab use in generalised pustular psoriasis flares.
    Lancet. 2024;404:846-847.
    >> Share

  23. MANN GB, Rose AK, Zdenkowski N
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
    Lancet. 2024;404:526.
    >> Share

  24. KUNKLER I, Cameron D, Dixon M, Williams L, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525.
    >> Share

  25. SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525-526.
    >> Share

  26. MO DC, Huang JF, Luo PH, Wang HL, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:524-525.
    >> Share

  27. RENERT-YUVAL Y, Guttman-Yassky E
    Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
    Lancet. 2024;404:409-411.
    >> Share

    July 2024
  28. RUGO HS, Bardia A, Tolaney S
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
    Lancet. 2024;404:339-340.
    >> Share

  29. HARADA K, Ozaki A, Tanimoto T
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:339.
    >> Share

  30. MESSORI A
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338-339.
    >> Share

  31. GU Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338.
    >> Share

  32. ERGUN Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:337-338.
    >> Share

  33. ZUBERBIER T, Ensina LF, Gimenez-Arnau A, Grattan C, et al
    Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment.
    Lancet. 2024;404:393-404.
    >> Share

  34. BRUNNER PM
    A novel treatment approach for atopic dermatitis.
    Lancet. 2024 Jul 25:S0140-6736(24)01488-0. doi: 10.1016/S0140-6736(24)01488.
    >> Share

  35. SILVERBERG JI, Wollenberg A, Reich A, Thaci D, et al
    Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Lancet. 2024 Jul 24:S0140-6736(24)01203-0. doi: 10.1016/S0140-6736(24)01203.
    >> Share

  36. BISSONNETTE R, Warren RB, Pinter A, Agner T, et al
    Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
    Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027.
    >> Share

    June 2024
  37. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    >> Share

  38. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    >> Share

    May 2024
  39. BHUTTA MF, Leach AJ, Brennan-Jones CG
    Chronic suppurative otitis media.
    Lancet. 2024;403:2339-2348.
    >> Share

  40. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    >> Share

  41. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    >> Share

  42. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.
    >> Share

  43. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.
    >> Share

  44. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.
    >> Share

  45. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.
    >> Share

  46. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.
    >> Share

  47. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.
    >> Share

    April 2024
  48. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    >> Share

  49. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    >> Share

  50. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    >> Share

  51. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    >> Share

  52. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    >> Share

  53. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    >> Share

    March 2024
  54. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    >> Share

  55. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    >> Share

  56. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    >> Share

  57. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

    February 2024
  58. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016